JD Supra

Final FDA combination product guidance encourages application-based feedback pathways

The U.S. Food and Drug Administration (FDA) recently finalized its guidance entitled “Requesting Food and Drug Administration Feedback on Combination Products,” stressing as it did in the draft ...
Nasdaq

Final Phase 2 Data Show Durability of Response for Casdozokitug in Combination with Atezolizumab and Bevacizumab in Hepatocellular Carcinoma by Coherus BioSciences

Final Phase 2 data show casdozokitug with atezolizumab/bevacizumab achieves a 17.2% complete response rate in HCC patients. Coherus BioSciences, Inc. announced ...
Business Wire

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX ...
Nasdaq

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

REDWOOD CITY, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS), today announced final data from its Phase 2 open label clinical trial evaluating casdozokitug ...